June 2024 in “British Journal of Dermatology” Dupilumab can both cause and treat alopecia areata, with many patients experiencing hair regrowth.
25 citations
,
May 2019 in “Biologics” Dupilumab can cause rare side effects like a rash on the face and neck.
January 2020 in “International Journal of Research in Pharmacy and Chemistry” A reliable method was created to measure dutasteride and related molecules in capsules.
18 citations
,
October 2019 in “European Journal of Dermatology”
15 citations
,
October 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
72 citations
,
March 2023 in “Biomolecules” Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.
2 citations
,
January 2024 in “SAGE Open Medical Case Reports” Dupilumab can cause lupus-like symptoms, so patients need careful monitoring.
Dupilumab may worsen hair loss in patients with alopecia areata.
49 citations
,
December 2018 in “JAAD case reports” Dupilumab may cause significant hair loss, which can reverse after stopping the drug.
20 citations
,
July 2024 in “Archives of Dermatological Research” Dupilumab helps children with alopecia areata regrow hair safely.
Dupilumab may cause hair loss, so patients should be monitored.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
2 citations
,
June 2022 in “Journal of cosmetic dermatology” Dupilumab can help hair regrowth but may also trigger alopecia areata.
September 2024 in “Вопросы современной педиатрии” Dupilumab helped an 11-year-old boy regrow hair and reduce skin rashes.
5 citations
,
July 2024 in “Pediatric Dermatology” Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.
March 2021 in “International Journal of Clinical Dermatology & Research” Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.
New methods efficiently isolate dermal papilla cells from hair follicles, preserving their characteristics better than traditional methods.
July 2025 in “Ultrasound in Medicine & Biology” UTMD with diclofenac and Doxil® improves cancer treatment by boosting immune response and reducing tumor-supporting cells.
61 citations
,
January 2013 in “International Journal of Biological Macromolecules” Combining DHT and EDC improves the strength and stability of PADM scaffolds for tissue engineering.
49 citations
,
December 2018 in “Journal of Investigational Allergology and Clinical Immunology” Dupilumab may cause hair loss in some patients with severe atopic dermatitis.
March 2005 in “Journal of The American Academy of Dermatology” Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.
27 citations
,
December 2015 in “Clinical and Experimental Dermatology” Diphencyprone helped most patients with alopecia areata regrow some hair.
15 citations
,
February 2024 in “Journal of Dermatological Treatment” Dupilumab may help treat alopecia areata without needing high IgE levels.
June 2025 in “Journal of Drug Delivery Science and Technology” A dissolving microneedle patch with dutasteride offers effective, long-lasting hair loss treatment with fewer side effects.
53 citations
,
January 2018 in “JAAD case reports” Dupilumab for eczema may cause hair loss.
10 citations
,
October 2024 in “Dermatology Practical & Conceptual” Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.
November 2024 in “Dermatology Online Journal” Dupilumab may help treat alopecia areata, but more research is needed.
37 citations
,
September 2009 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.
January 2026 in “Acta Dermato Venereologica” Dupilumab effectively treats severe skin issues in a rare genetic disorder.
Polydopamine is promising for personalized medicine and biomedical technology due to its strong adhesion and biocompatibility.